Validation of the 6 min walk test according to the OMERACT filter: a systematic literature review by the EPOSS-OMERACT group

Objective To assess the validity of the 6 min walk test (6MWT) in pulmonary arterial hypertension secondary to systemic sclerosis (PAH-SSc) according to the OMERACT filter. Methods A systematic literature search was conducted from 1966 through June 2009. The assessment of validation of the 6MWT was based on the OMERACT filter criteria with the domains ‘truth’, ‘discrimination’ and ‘feasibility’. Results From the 57 articles identified, 9 (16%) were analysed. The 6MWT had face validity as it has been accepted by the registration agencies as a surrogate of PAH-SSc. It was sensitive to change in response to therapy, with effect sizes ranging from 0.30 to 1.37 with a parallel variation of haemodynamic parameters measured by right heart catheterisation. Feasibility was also validated. Content validity was not confirmed as this test was not specific for PAH-SSc. There was some evidence that 6MWT might meet criterion/construct validity, reproducibility and sensitivity to change over time, but insufficient data were provided to fully validate these components. Conclusions Current evidence suggests partial validation of the 6MWT in PAH-SSc according to the OMERACT filter. Further dedicated studies are needed to validate completely the 6MWT in PAH-SSc, taking into account the comorbidities interfering with the 6MWT.

[1]  Y. Allanore,et al.  Lack of Specificity of the 6-Minute Walk Test as an Outcome Measure for Patients with Systemic Sclerosis , 2009, The Journal of Rheumatology.

[2]  C. Strange,et al.  Limitations to the 6-Minute Walk Test in Interstitial Lung Disease and Pulmonary Hypertension in Scleroderma , 2009, The Journal of Rheumatology.

[3]  J. Seibold,et al.  The 6-minute walk test in scleroderma--how measuring everything measures nothing. , 2008, Rheumatology.

[4]  Oliver Distler,et al.  Defining appropriate outcome measures in pulmonary arterial hypertension related to systemic sclerosis: a Delphi consensus study with cluster analysis. , 2008, Arthritis and rheumatism.

[5]  R. Barst,et al.  Sildenafil for pulmonary arterial hypertension associated with connective tissue disease. , 2007, The Journal of rheumatology.

[6]  R. Barst,et al.  Selective endothelinA receptor antagonism with sitaxsentan for pulmonary arterial hypertension associated with connective tissue disease , 2007, Annals of the rheumatic diseases.

[7]  Y. Allanore,et al.  New therapeutic strategies in the management of systemic sclerosis , 2007, Expert opinion on pharmacotherapy.

[8]  A. L. de Sá Pinto,et al.  Reduced exercise capacity in systemic sclerosis patients without pulmonary involvement , 2007, Scandinavian journal of rheumatology.

[9]  D. Furst,et al.  Submaximal exercise testing in the assessment of interstitial lung disease secondary to systemic sclerosis: reproducibility and correlations of the 6-min walk test , 2006, Annals of the rheumatic diseases.

[10]  M. Humbert,et al.  Bosentan treatment for pulmonary arterial hypertension related to connective tissue disease: a subgroup analysis of the pivotal clinical trials and their open-label extensions , 2006, Annals of the rheumatic diseases.

[11]  Y. Allanore,et al.  Radiological hand involvement in systemic sclerosis , 2006, Annals of the rheumatic diseases.

[12]  C. Denton,et al.  Systemic sclerosis associated pulmonary hypertension: improved survival in the current era , 2005, Heart.

[13]  S. Rich,et al.  Treprostinil, a prostacyclin analogue, in pulmonary arterial hypertension associated with connective tissue disease. , 2004, Chest.

[14]  M. Suarez‐Almazor,et al.  Current status of outcome measure development for clinical trials in systemic sclerosis. Report from OMERACT 6. , 2003, The Journal of rheumatology.

[15]  Stuart Rich,et al.  Continuous Intravenous Epoprostenol for Pulmonary Hypertension Due to the Scleroderma Spectrum of Disease , 2000, Annals of Internal Medicine.

[16]  P. Tugwell,et al.  The OMERACT filter for Outcome Measures in Rheumatology. , 1998, The Journal of rheumatology.

[17]  A R Jadad,et al.  Assessing the quality of reports of randomized clinical trials: is blinding necessary? , 1996, Controlled clinical trials.

[18]  R. Barst,et al.  Selective endothelin A receptor antagonism with sitaxsentan for pulmonary arterial hypertension associated with connective tissue disease. , 2007, Annals of the rheumatic diseases.

[19]  P. Sampaio-Barros,et al.  Six-minute walk test for the evaluation of pulmonary disease severity in scleroderma patients. , 2007, Chest.

[20]  F. Balsano,et al.  Pulmonary hypertension is associated with impaired exercise performance in patients with systemic sclerosis , 2000, Scandinavian journal of rheumatology.